The introduction of new vaccines into developing countries. IV: Global Access Strategies

Vaccine

Volumn 25, Issue 20, 2007, Pages 4003-4011

  Mahoney, Richard T ^a   Krattiger, Anatole ^b   Clemens, John D ^a   Curtiss III, Roy ^b  

^a International Vaccine Institute   (South Korea)

^b ARIZONA STATE UNIVERSITY   (United States)

Author keywords

Access; Developing country; Innovation; Vaccine

Indexed keywords

DENGUE VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS C VACCINE; PNEUMOCOCCUS VACCINE;

ARTICLE; CLINICAL TRIAL; DENGUE; DEVELOPING COUNTRY; DRUG COST; FLAVIVIRUS; HEALTH CARE NEED; HEALTH CARE ORGANIZATION; HEALTH CARE PLANNING; HEPATITIS B; HUMAN; IMMUNE RESPONSE; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; PRODUCT DEVELOPMENT; SALMONELLA;

DENGUE VACCINES; DEVELOPING COUNTRIES; HEALTH PLANNING; HEALTH SERVICES ACCESSIBILITY; IMMUNIZATION PROGRAMS; PNEUMOCOCCAL VACCINES; PNEUMONIA, BACTERIAL; PRIVATE SECTOR; PUBLIC SECTOR; VACCINES; WORLD HEALTH;

EID: 34247208505     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.02.047     Document Type: Article

References (39)

1. Mahoney R., and Maynard J.E. The introduction of new vaccines into developing countries. Vaccine 17 7-8 (1999) 646-652
2. Mahoney R., Ramachandran S., and Xu Z.Y. The introduction of new vaccines into developing countries. II. Vaccine financing. Vaccine 18 24 (2000) 2625-2635
3. Mahoney R., Pablos-Mendez A., and Ramachandran S. The introduction of new vaccines into developing countries. III: The role of intellectual property. Vaccine 22 5-6 (2004) 786-792
4. Levine O.S., O'Brien K.L., Knoff M., Adegbola R.A., Black S., Thomas C., et al. Pneumococcal vaccination in developing countries. Lancet 367 9526 (2006) 1880-1882
5. Murphy T.F., Bakaletz L.O., Kyd J.M., Watson B., and Klein D.L. Vaccines for otitis media: proposals for overcoming obstacles to progress. Vaccine 23 21 (2005) 2696-2702
6. Cripps A.W., Leach A.J., and Lehmann D. Pneumococcal vaccination in developing countries. Lancet 368 9536 (2006) 644
7. Cutts F.T., Zamzn S.M.A., Enwere G., Jaffar S., Levine O.S., Okoko J.B., et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in the Gambia: randomised, double-blind, placebo-controlled trial. Lancet 365 9465 (2005) 1139-1146
8. Cripps A.W., Leach A.J., Lehmann D., and Benger N. Fifth international symposium on pneumococci and pneumococcal diseases. Alice Springs, Central Australia, 2-6 April 2006 (2006) 10.1016/j.vaccine.2006.09.001
9. Gubler D.J., and Meltzer M. Impact of dengue/dengue hemorrhagic fever on the developing world. Adv Virus Res 53 (1999) 35-70
10. Schumpeter J. Capitalism, socialism and democracy (1943), Allen & Uwin, London
11. Freeman C. Technology policy and economic performance: lessons from Japan (1987), Pinter Publishers, London and New York 155
12. In: Nelson R.R. (Ed). National innovation systems: a comparative analysis (1993), Oxford University Press, New York and Oxford 541
13. Lall, S, Indicators of the relative importance of IPRs in developing countries. UNCTAD-ICTSD Project on IPRs and sustainable development; 2003 [issue paper No. 3].
14. Lall S. Technological change and industrialization in the Asian newly industrializing economies: achievements and challenges. In: Kim L.a.R.R.N. (Ed). Technology, learning & Innovation, (2000), Press Syndicate of the University of Cambridge, Cambridge 13-68
15. Lall S. Developing countries as exporters of industrial technology. Res Pol 9 (1980) 24-52
16. Lall S. Technological capabilities and industrialization. World Devel 20 2 (1992) 165-186
17. Lall S., and Teubal M. "Market-Stimulating" technology policies in developing countries: a framework with examples from East Asia. World Devel 26 8 (1998) 1369-1385
18. Mahoney R., Lee K., and Yun M.K. The evolution of biotechnology in Korea: a framework for analysis; a case study of the vaccine industry. Innovation Strategy Today (2005)
19. Mahoney R., and Morel C.M. A global health innovation system. Innovation Strategy Today 2 1 (2006) 1-12
20. Morel C.M., Acharya T., Broun D., Dangi A., Elias C., Ganguly N.K., et al. Health innovation networks to help developing countries address neglected diseases. Science 309 5733 (2005) 401-404
21. Lall S. Indicators of the relative importance of IPRs in developing countries. Intellectual property rights and sustainable development (2003), International Centre for Trade and Sustainable Development, Geneva
22. Mahoney R. Policy analysis: an essential research tool for the introduction of vaccines in developing countries. J Health Popul Nutr (2004) 22
23. DiMasi J.A. Risks in new drug development: approval success rates for investigational drugs. Clin Pharmacol Ther 69 5 (2001) 297-307
24. Towse A., and Kettler H. Advance price or purchase commitments to create markets for treatments for diseases of poverty: lessons from three policies. Bull World Health Organ 83 4 (2005) 301-307
25. Lee J., Bae Z.-T., and Choi D.-K. Technology development processes: a model for a developing country with global perspective. R&D Management 18 (1988) 235-250
26. Muraskin W. The war against Hepatitis B. (1995), The University of Pennsylvannia Press, Philadelphia p. 248
27. Mahoney R.T. Cost of plasma-derived hepatitis B vaccine production. Vaccine 8 4 (1990) 397-401
28. Mahoney R.T. Public-private partnership in the development of Hepatitis B vaccine in Korea: implications for developing countries. Science, Technology & Society 10 1 (2005) 129-140
29. Nelsen L. Ensuring developing country access to new inventions: the role of patents and the power of public sector research institutions. In: Krattiger A.F. (Ed). Handbook of best practices for management of, IP., in health, agriculture (2006), MIHR and PIPRA: Oxford, San Francisco
30. Krattiger A. Global access strategy for the live recombinant attenuate Salmonella anti-pneumococcal vaccine for newborns. Biodesign Institute, Arizona State University, Tempe. 2006
31. Anonymous. Strategic plan. Dengue vaccines: The role of the Pediatric Dengue Vaccine Initiative. Strategic partnerships, supportive research & development, evaluation, and access. http://www.pdvi.org/strategicplan; 2006 [cited].
32. Oehler, J, The role of milestones in licensing deals to assure access to health products in developing countries. IP Strategy Today. http://www.bioDevelopments.org/ip (10-2004); 2004:59-70.
33. Krattiger A., Kowalski S., Eiss R., and Taubman A. Intellectual property management strategies to accelerate the development and access of vaccines and diagnostics: case studies on pandemic influenza, malaria and SARS. Innovation Strategy Today 2 (2006) 2
34. Kettler, H, White K, Jordan S, Valuing industry contributions to public-private partnerships for health product development. The initiative on public-private partnerships for health, global forum for health research; 2003.
35. Moran M., and Guzman J. The new landscape of neglected diseases (2005), Wellcome Trust, London
36. Buse K., and Walt G. Global public-private partnerships. Part II: What are the health issues for global governance?. Bull World Health Organ 78 5 (2000) 699-709
37. Nwaka S., and Ridley R.G. Virtual drug discovery and development for neglected diseases through public-private partnerships. Nat Rev Drug Discov 2 (2003) 919-927
38. In: Mahoney R. (Ed). Handbook for the management of intellectual property in health research and development (2003), Centre for the Management of IP in Health R&D, Oxford 275
39. Spielman D. Systems of Innovation: models, methods and future directions. Innovation Strategy Today 2 1 (2006) 41-54